Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)
Public ClinicalTrials.gov record NCT01665144. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Variable Treatment Duration Study Evaluating the Efficacy and Safety of Siponimod (BAF312) in Patients With Secondary Progressive Multiple Sclerosis Followed by Extended Treatment With Open-label BAF312.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Evaluate the safety and efficacy of Siponimod (BAF312) versus placebo in a variable treatment duration in patients with secondary progressive multiple sclerosis (Core Part) followed by extended treatment with open-label BAF312 to obtain data on long-term safety, tolerability and efficacy (Extension Part).
Study identification
- NCT ID
- NCT01665144
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,651 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 60 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 20, 2012 (Actual)
- Primary completion
- Apr 29, 2016 (Actual)
- Completion
- Mar 31, 2023 (Actual)
- Last update posted
- Jun 5, 2024
2012 – 2023
United States locations
- U.S. sites
- 52
- U.S. states
- 25
- U.S. cities
- 48
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novartis Investigative Site | Phoenix | Arizona | 85032 | — |
| Novartis Investigative Site | Berkeley | California | 94705 | — |
| Novartis Investigative Site | Los Angeles | California | 90033 | — |
| Novartis Investigative Site | Oceanside | California | 92056 | — |
| Novartis Investigative Site | Sacramento | California | 95817 | — |
| Novartis Investigative Site | Aurora | Colorado | 80045 | — |
| Novartis Investigative Site | Basalt | Colorado | 81621 | — |
| Novartis Investigative Site | Boulder | Colorado | 80301 | — |
| Novartis Investigative Site | Colorado Springs | Colorado | 80907 | — |
| Novartis Investigative Site | Englewood | Colorado | 80113 | — |
| Novartis Investigative Site | Fairfield | Connecticut | 06824 | — |
| Novartis Investigative Site | Delray Beach | Florida | 33445 | — |
| Novartis Investigative Site | Hollywood | Florida | 33024 | — |
| Novartis Investigative Site | Jacksonville | Florida | 32209 | — |
| Novartis Investigative Site | Maitland | Florida | 32751 | — |
| Novartis Investigative Site | Ormond Beach | Florida | 32174 | — |
| Novartis Investigative Site | Port Charlotte | Florida | 33952 | — |
| Novartis Investigative Site | Tampa | Florida | 33609 | — |
| Novartis Investigative Site | Tampa | Florida | 33612 | — |
| Novartis Investigative Site | Vero Beach | Florida | 32960 | — |
| Novartis Investigative Site | Chicago | Illinois | 60612 | — |
| Novartis Investigative Site | Evanston | Illinois | 60201 | — |
| Novartis Investigative Site | Flossmoor | Illinois | 60422 | — |
| Novartis Investigative Site | Lenexa | Kansas | 66212 | — |
| Novartis Investigative Site | Baltimore | Maryland | 21287 | — |
| Novartis Investigative Site | Ann Arbor | Michigan | 48109 | — |
| Novartis Investigative Site | Detroit | Michigan | 48201 | — |
| Novartis Investigative Site | Detroit | Michigan | 48202 2689 | — |
| Novartis Investigative Site | Plymouth | Minnesota | 55446 | — |
| Novartis Investigative Site | St Louis | Missouri | 63131 | — |
| Novartis Investigative Site | Las Vegas | Nevada | 89106 | — |
| Novartis Investigative Site | Lebanon | New Hampshire | 03756 | — |
| Novartis Investigative Site | Freehold | New Jersey | 07728 | — |
| Novartis Investigative Site | Albuquerque | New Mexico | 87131-0001 | — |
| Novartis Investigative Site | New York | New York | 10017 | — |
| Novartis Investigative Site | New York | New York | 10029 | — |
| Novartis Investigative Site | Patchogue | New York | 11772 | — |
| Novartis Investigative Site | Stony Brook | New York | 11794 | — |
| Novartis Investigative Site | Charlotte | North Carolina | 28207 | — |
| Novartis Investigative Site | Akron | Ohio | 44320 | — |
| Novartis Investigative Site | Dayton | Ohio | 45408 | — |
| Novartis Investigative Site | Portland | Oregon | 97225 | — |
| Novartis Investigative Site | Springfield | Oregon | 97477 | — |
| Novartis Investigative Site | Philadelphia | Pennsylvania | 19104 | — |
| Novartis Investigative Site | Providence | Rhode Island | 02905 | — |
| Novartis Investigative Site | Dallas | Texas | 75216 | — |
| Novartis Investigative Site | Lubbock | Texas | 79410 | — |
| Novartis Investigative Site | San Antonio | Texas | 78258 | — |
| Novartis Investigative Site | Burlington | Vermont | 05401 | — |
| Novartis Investigative Site | Seattle | Washington | 98101 | — |
| Novartis Investigative Site | Seattle | Washington | 98122 | — |
| Novartis Investigative Site | Milwaukee | Wisconsin | 53215 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 238 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01665144, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 5, 2024 · Synced Oct 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01665144 live on ClinicalTrials.gov.